x
ServiziMenu principaleHome
Home > Sponsors & Exhibition > Sponsored satellite symposia
Print

Sponsored satellite symposia

Thursday, 14 November


9:00 -10:30 Sponsored satellite symposium 1 Touchime

AstraZeneca

Are we moving towards true optimization of CDK4/6 inhibition in high-risk patients with HR+/HER2- advanced breast cancer?

  9:00 Introduction and welcome (Chair: P. Neven, BE)
  9:10 How can we select the most appropriate CDK4/6 inhibitor and treatment sequencing in patients with 
          HR+/HER2- ABC? (S. Dawood, UAE - R. Bartsch, AT)
  9:35 How different are the AE profiles for the CDK4/6 inhibitors and what impact do they have on monitoring and
          adherence? (P. Neven, BE)
10:00 How might upcoming guidelines be updated in light of recent data? (P. Neven, BE - S. Dawood, UAE - R.
          Bartsch, AT)
10:25 Summary and close (P. Neven, BE)

Symposium faculty
P. Neven, Universitair Ziekenhuis Leuven, Leuven, Belgium
S. Dawood, Dubai Medical College, Dubai, United Arab Emirates
R. Bartsch, Medical University of Vienna, Vienna, Austria



11:00 -12:30
Sponsored satellite symposium 2 Novartis

AstraZeneca

Progress in HR+/HER2- advanced breast cancer: hopes and challenges in clinical practice

11:00 Welcome (L. Costa, PT)
11:05 Panel I. Progress in HR+ HER2- aBC: Translating cancer biology knowledge into benefit for patients
         - Presentation (R. de Boer, AU)
         - Interactive panel discussion (R. de Boer, AU - L. Costa, PT - P. Fasching, DE - M. Tuthill, UK - Andrew
           Wardley, UK)
11:35 Panel II. Progress in HR+ HER2- aBC: the evolving role of biomarkers
         - Presentation (P. Fasching, DE)
         - Interactive panel discussion (R. de Boer, AU - L. Costa, PT - P. Fasching, DE - M. Tuthill, UK - Andrew
           Wardley, UK)
12:05 Progress in HR+ HER2- aBC: how will the future look like?
         - Interactive panel discussion (R. de Boer, AU - L. Costa, PT - P. Fasching, DE - M. Tuthill, UK - Andrew
            Wardley, UK)
12:25 Closing remarks (L. Costa, PT)


Symposium faculty
Luis Costa
, Centro Hospitalar de Lisboa Norte - Hospital de Santa Maria, Lisbon, Portugal
Richard De Boer, Peter MacCallum Cancer Centre, Melbourne, Australia
Peter Fasching, University Hospital Erlangen, Germany
Mark Tuthill, Churchill Hospital, Oxford, United Kingdom
Andrew Wardley, The Christie Hospital, Manchester, United Kingdom




18:00 -19:30 Sponsored satellite symposium 3 Daiichi Sankyo Europe

AstraZeneca

HER2 targeted therapies in metastatic Breast Cancer - Current Status and Emerging Options
Chair: Chris Twelves, UK

18:00 Introduction + objectives of the meeting (Chris Twelves, UK)
18:10 Current challenges in HER2 targeted therapies – where do we need further improvement?
          - The clinician’s perspective (Sofia Braga, PT)
          - The pathologist’s perspective (Giuseppe Viale, IT)
18:40 How can new technologies fill the medical gap in HER driven metastatic Breast Cancer? (Peter Fasching, DE)
18:55 Clinical study programs to optimize personalized medicine in Her2 metastatic breast cancer
          (Jean-Yves Pierga, FR)
19:10 Panel discussion (All and moderated by Chris Twelves, UK)
19:25 Key take away and closing (Chris Twelves, UK)

Symposium faculty
Chris Twelves, Clinical Cancer Pharmacology and Oncology, Leeds, United Kingdom
Giuseppe Viale, San Raffaele Scientific Institute, Milan, Italy
Peter Fasching, University Erlangen, Erlangen, Germany
Jean-Yves Pierga, Institut Curie, Paris, France
Sofia Braga, Minho University, Braga, Portugal